Physician-scientist receives NCI grant to advance cell-based cancer treatments
Grant and Award Announcement
Updates every hour. Last Updated: 30-Apr-2025 20:08 ET (1-May-2025 00:08 GMT/UTC)
Metastasis is responsible for 90 percent of cancer deaths. Researchers have found that the mutations driving it may stem from a commonly inherited variant of the PCSK9 gene.
For the first time, researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient’s response to CAR T cell therapy in real time. The organoid’s response to therapy mirrored the response of the actual tumor in the patient’s brain. That is, if the tumor-derived organoid shrunk after treatment, so did the patient’s actual tumor.
Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty liver disease – a liver-specific type and a systemic type that affects other organs and tissues. The discovery could lead to improved diagnosis and treatment of this growing patient group. Two studies are published back-to-back in Nature Medicine.
A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells. This discovery — published today, Dec. 9, in Nature Biotechnology — could unveil an entirely different understanding of the origins of cancer within the body, as well as offer groundbreaking insight into new treatment strategies that could target the growth of tumors in their earliest stages. A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells. This discovery — published today, Dec. 9, in Nature Biotechnology — could unveil an entirely different understanding of the origins of cancer within the body, as well as offer groundbreaking insight into new treatment strategies that could target the growth of tumors in their earliest stages.
Dana-Farber Cancer Institute researchers are breaking new ground in the fight against systemic mastocytosis, a rare and heterogeneous condition that is often challenging for clinicians to accurately diagnose and treat.